8X

Quick links to important sections

8X

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of 8X

Property Description
Active ingredient Ciclopirox, Pyrithione Zinc
Form Medicated shampoo
Pharmacological class Antifungal, Antiseborrheic Agent
Common purpose Managing scalp imbalances and flaking
Origin Synthetic combination product

What Type of Medicine is 8X? (Definition, Form, and Classification)

8X is defined as a topical combination medicinal product specifically formulated as a medicated shampoo for external use on the scalp. It belongs to the high-level pharmacological class of antifungal and antiseborrheic agents. Both Ciclopirox and Pyrithione Zinc are synthetic compounds utilized in an aqueous vehicle, distinguishing this pharmaceutical preparation from non-medicated or purely cosmetic products. The topical route of administration ensures that the active components are delivered directly to the target area on the skin surface.


The Active Composition: Ciclopirox and Pyrithione Zinc

The product contains two distinct active ingredients: Ciclopirox and Pyrithione Zinc (ZPTO). Ciclopirox is a synthetic hydroxypyridone derivative recognized for its broad-spectrum action against various yeasts and fungi. Pharmacological studies indicate Ciclopirox's ability to inhibit the growth of common dermatophytes and fungi associated with scalp conditions. This means Ciclopirox helps to stop the reproduction of problematic microorganisms. Pyrithione Zinc is a coordination complex with established antimycotic and bacteriostatic properties. Zinc Pyrithione is utilized for its ability to reduce scaling and shedding. This means Pyrithione Zinc effectively helps to control flaking and visible scales on the scalp.


General Therapeutic Function and Purpose

The general therapeutic purpose of 8X is to manage scalp conditions by targeting two primary biological factors: the overgrowth of specific microorganisms and the accelerated shedding of skin cells. The use of this dual antifungal and antiseborrheic formulation is intended for providing management of complex scalp imbalances. This integrated action, combining the fungus-stopping properties of Ciclopirox with the skin-normalizing effects of Pyrithione Zinc, is intended to provide symptom relief associated with complex scalp imbalances.

Regulatory References

  1. Zinc Pyrithione information

What side effects are possible with 8X?

Possible side effects and safety information

The safety profile for this topical medicated shampoo, which contains Ciclopirox and Pyrithione Zinc, is primarily characterized by localized reactions at the application site. The official regulatory documents list adverse reactions based on clinical trial data and subsequent post-marketing experience.


Adverse Reaction Scope

Category Documented Effects
Most Frequent Adverse Events Pruritus (itching, including increased itching), a burning sensation, and erythema (redness) were reported during clinical trials. These are classified as the most frequent adverse events.
Post-Marketing Observations Reactions reported after market approval include hair discoloration, particularly noted in patients with lighter hair color, abnormal hair texture, alopecia (hair loss), and rash. The frequency of these observations is not reliably estimated.

Safety Considerations for Specific Populations

Safety data is constrained for certain groups according to regulatory documentation:

  • Pregnancy and Lactation: The product is categorized as Pregnancy Category B. Caution is advised for nursing mothers, as it is unknown whether the active ingredients are excreted in human milk.
  • Pediatric Use: No formal clinical trials have been conducted to establish safety in subjects younger than 16 years of age.
  • Geriatric Use: While clinical trial data showed comparable safety in older adults, the possibility of greater sensitivity in some older individuals cannot be ruled out.

Restrictions and Discontinuation Criteria

Hypersensitivity to any component is a regulatory contraindication. Furthermore, if any reaction suggesting sensitivity or chemical irritation occurs locally, the official safety guidelines indicate that the product should be discontinued. These restrictions define the specific safety boundaries for the use of this medicine.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for 8X medicated shampoo is strictly defined by the regulatory documentation for accidental oral ingestion. Regulatory sources confirm that swallowing the topical product may cause harm. Overdose manifestations that are officially documented as requiring immediate action include severe systemic effects such as trouble breathing (respiratory distress) or passing out (loss of consciousness).


Mandated Emergency Actions

Official instructions require the user to seek immediate medical attention following any suspected ingestion. For the onset of serious or life-threatening symptoms, the mandated action is to immediately call 911 or local emergency services. It is further instructed to contact a poison control center right away and visit an emergency room at once for formal medical evaluation and monitoring.


Management and Procedural Constraints

In the event of ingestion, management focuses on providing supportive and symptomatic measures. Due to the nature of the shampoo and the inherent risk of aspiration (inhaling liquid into the lungs), regulatory guidance cautions against performing procedures such as induced vomiting (emesis) or gastric lavage. Regulatory information confirms that no specific antidote is known for the active ingredients in an overdose scenario.

Therapeutic Uses of 8X

What 8X Treats: Main Uses and Benefits

The active ingredients in this formulation are commonly used in the symptomatic management of chronic scalp conditions. This medication is relevant for easing symptoms associated with seborrheic dermatitis of the scalp and dandruff. It is commonly used across conditions characterized by periods of heightened symptoms, offering supportive relief for manifestations related to physical discomfort like excessive scaling, flaking, noticeable scalp itchiness, and associated redness and irritation.

The shampoo is relevant when supportive symptom management is appropriate, used in situations involving recurrent or episodic manifestations. It is applied during phases when symptoms become more noticeable. This usage may assist with maintaining a sense of stability and contributes to easing the overall symptom load in conditions involving inflammatory or irritative processes.


Quick Fact: Symptom Relief Focus
This medication is primarily used to help manage the visible and discomforting symptoms of scaling and flaking, alongside noticeable itchiness (pruritus), offering support during periods of heightened symptoms in conditions associated with acute or episodic changes.

Eligibility and Restrictions for Use

Who can and cannot use 8X

The regulatory documentation defines specific eligibility criteria for the use of the Ciclopirox/Pyrithione Zinc medicated shampoo (8X).

Absolute Contraindication

Use of this product is contraindicated in individuals with a known hypersensitivity or allergy to Ciclopirox, Pyrithione Zinc, or any other component in the formulation.

Age-Related Eligibility

The medicine is indicated for use in adults only. Safety and effectiveness in the pediatric population (subjects younger than 16 years of age) have not been established in clinical trials. For older adults (65 years and older), while safety and tolerability were comparable to younger subjects, efficacy was not demonstrated in this sub-group.

Restricted and Conditional Use

  • Pregnancy Status: Use is considered conditional and is permitted only if clearly needed.
  • Lactation Status: Caution should be exercised when administered to a nursing woman, as it is not known whether the active ingredients are excreted in human milk.
  • Immunological Status: There is no relevant clinical experience established for use in patients who are immunocompromised or have a history of immunosuppression.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for 8X, a topical medicinal product containing Ciclopirox and Pyrithione Zinc, is characterized by a formal determination of minimal systemic risk. This classification is consistently supported by data in official government prescribing information, such as documents published by the U.S. Food and Drug Administration (FDA) and DailyMed.


Interaction Scope

Category Official Regulatory Status
Medicinal product categories with documented interactions None documented.
Specific interacting medicines (if explicitly listed) None explicitly listed.
Mechanistic basis of interactions Systemic interactions are not expected due to minimal systemic absorption after topical application.
Timing-based interaction rules None documented.
Population-specific interaction notes None documented.
Interaction-related restrictions None documented.

Resulting Interaction Structure

Official Interaction Statements:

  • Systemic drug interactions are not expected with this topical formulation.
  • The minimal systemic exposure to Ciclopirox following topical application, with total urinary excretion measured at less than 0.5% of the administered dose, is the regulatory basis for the lack of expected systemic interaction.
  • The official label specifies no medicinal products formally designated as contraindicated for co-administration.
  • No specific pharmacokinetic interactions (e.g., those mediated by CYP enzymes or transporters) are documented in the official regulatory prescribing information.

Connection to the overall interaction profile:

The established regulatory profile for 8X is defined by the official finding of minimal systemic absorption. This characteristic supports the official statement that systemic drug–drug interactions are not expected, resulting in a profile that contains no formally documented restrictions, timing requirements, or prohibited combinations with other medicines within governmental labels.

Mechanism of Action

The mechanism of 8X is a pharmacodynamic synergy achieved by the two active ingredients, Ciclopirox and Pyrithione Zinc, which collectively target microbial metabolism and host epidermal proliferation.


Targeted Fungal Energy Pathway Disruption

This domain covers the antifungal mechanism where Ciclopirox acts by chelating essential ferric iron ( Fe^3+) ions and disrupting fungal cell membrane transport. This action leads to the immediate failure of the fungal mitochondrial respiratory chain, halting ATP synthesis and resulting in fungal cellular demise. Pyrithione Zinc complements this by acting as an ionophore, further accelerating energy failure.


Host Epidermal Cell Turnover Modulation

This domain addresses the unique antiseborrheic mechanism provided by Pyrithione Zinc, which exerts a cytostatic action by subtly interfering with the host's keratinocyte mitotic apparatus. This mechanism reduces the accelerated rate of cell division and maturation, facilitating adjustment of the scalp's epithelial turnover time toward a regulated state.


Mechanistic Synergy and Combined Physiological Effect

The two mechanisms are functionally complementary: the fungal energy pathway disruption causes fungal cellular demise, while the cell turnover modulation directly modulates the host's hyper-proliferative response. This coordinated action facilitates the regulation of the scalp surface environment.

Dosage and Administration Information

How to Use 8X: Official Administration Guidelines

8X is a topical combination product used according to a standardized schedule established for the management of scalp conditions. The official instructions define the route, volume, frequency, and contact time required for administration.


Usage Protocol and Dosage

The product is for topical use only on the scalp. It must not be used for ophthalmic or oral administration. The medicine is indicated for use in adults (16 years and older).

The standard regimen requires an application volume of approximately 1 teaspoon (5 mL) per treatment; up to 2 teaspoons (10 mL) may be used for long hair. The shampoo is applied twice per week for a defined treatment duration, with a mandatory minimum interval of 3 days between consecutive applications.


Administration Method and Course Duration

Administration is a procedural sequence: the product is applied to wet hair, lathered, and must be allowed to remain on the scalp for a duration of 3 minutes before being thoroughly rinsed off. Contact with the eyes must be avoided during application. The full course of therapy is specified as 4 weeks. If a treatment is missed, the patient should resume the twice-weekly schedule, ensuring the minimum 3-day separation between treatments is observed. Continued use beyond the 4-week period is not included in the standard instructions and necessitates a re-evaluation.

Recent Clinical Evidence

8X: Recent Clinical Evidence

Evidence for Managing Seborrheic Dermatitis of the Scalp

Research exploring the active ingredients in 8X focuses on conditions characterized by fluctuating or episodic manifestations, such as seborrheic dermatitis. The evidence primarily comes from short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and involved a comparison between the medicated components and a non-medicated or vehicle shampoo. The study populations were primarily adults (18 years and older).

These trials monitored outcomes related to physical discomfort, specifically the measurement of clinical signs such as scaling, redness (erythema), and pruritus (itchiness). Research also examined patient-reported outcomes, collecting data on general perception and quality of life measures. Findings describe patterns related to measured changes in the severity of scaling and redness when the active components were compared to the control group in study participants.

Evidence for Managing Dandruff (Pityriasis Capitis)

Clinical evidence related to dandruff is frequently integrated with studies for mild seborrheic dermatitis. The research mainly consists of short-term Randomized Controlled Trials (RCTs), where studies monitored the effects of the active components against non-medicated control shampoos. These trials included adult populations presenting with moderate to severe dandruff.

Research examined outcomes focused on the precise quantification of scalp flaking using specialized scoring systems, alongside the measurement of associated pruritus (itchiness). Findings indicate that studies focusing on episodes where symptoms become more noticeable report measured differences in flaking scores when compared to the control group. Data also show patterns related to changes in the density of microorganism populations on the scalp.

Key Research Gaps and Uncertainties

Evidence primarily covers research exploring short-term symptom changes, typically over a study period of about four weeks. There is limited information available for long-term outcomes, meaning the durability of symptom control over many months or years of intermittent use is not fully established. Data for certain groups, especially pediatric populations, remain insufficient. The results apply only to the populations studied, and the research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Zinc Pyrithione drug information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about 8X (FAQ)


Q: Why is 8X prescribed instead of other medicines for the same condition?

Official product information describes 8X as containing two active ingredients: Ciclopirox, an antifungal agent, and Pyrithione Zinc, which acts as both an antifungal and an antiseborrheic agent. This combination provides a dual mechanism of action to manage scalp conditions, which is the foundational basis for its use.


Q: What kind of side effects are people most worried about with 8X?

Regulatory documents report adverse events based on what was observed in clinical studies. The most frequent adverse events reported were reactions at the application site, including local itching (pruritus), a burning sensation, and redness (erythema). These are the effects most commonly documented in the official safety profile.


Q: Does 8X start working right away?

While the active ingredients begin to work upon application, studies note that the full extent of clinical improvement may take up to 4 weeks of use. Following the labeled course duration is the expected condition for use described in official documents.


Q: Can 8X cause problems with sleeping?

The official label does not list specific sleep disturbances among the documented adverse events. This aligns with the understanding that the product is for topical use with minimal systemic exposure.


Q: Are there any common foods or drinks that should be avoided when taking 8X?

Systemic interactions with food or drink are not expected because the product is applied to the scalp and has minimal systemic absorption. The official label does not list any specific dietary restrictions or things to avoid.


Q: Does taking 8X require special blood tests or monitoring?

The official use instructions do not list any required blood tests or special monitoring of internal organ function while using this topical product. This aligns with the regulatory finding of minimal systemic exposure for this topical formulation.


Q: Is 8X considered a long-term medication?

No, according to the official product information, the standard course of therapy is specified as 4 weeks. The labeled instructions do not include continued use beyond this period.


Q: Are there different strengths or formulations of 8X available?

The combination product 8X is described in the official regulatory labeling as a medicated shampoo containing specific concentrations of Ciclopirox and Pyrithione Zinc for topical use.


Q: Can I take 8X if I have a history of liver issues?

Official guidance is not provided for individual use by people with existing medical conditions, including a history of liver issues. The product is for topical use only and official information confirms that systemic effects on internal organs are not expected due to minimal systemic absorption.


Q: Is 8X generally safe for older adults?

Official data indicates that in clinical studies, the safety and tolerability for older adults were comparable to younger subjects. However, regulatory documents note that the possibility of greater sensitivity in some older individuals cannot be ruled out.


Q: Is it normal to feel a bit nauseous when first starting 8X?

Nausea is not listed as one of the common or frequent adverse events in the regulatory documents for this product. Side effects are typically localized to the application site, such as burning or itching.


Q: Is 8X a controlled substance?

No. Official regulatory information from bodies like the Drug Enforcement Administration (DEA) confirms that the active ingredients in this topical formulation are not classified as a controlled substance.


Q: Can 8X be taken by people with kidney problems?

Official guidance is not provided for use by individuals with existing medical conditions such as kidney problems. The product is for topical use and official information confirms it has minimal systemic absorption, meaning systemic effects on internal organs are not expected.


Q: What does 'contraindication' mean for 8X?

A contraindication is a condition where use of the medicine is strictly prohibited. For 8X, the only absolute contraindication documented is a known hypersensitivity or allergy to any component of the shampoo.


Q: Do all people taking 8X experience side effects?

No. Clinical trial data indicates that not all people experience side effects. Adverse events are reported only in a percentage of the overall patient population studied.


Q: Can I drive while taking 8X?

No effects on the ability to drive or use machinery are anticipated. The official product information confirms that the active ingredients are not known to exert an effect on the central nervous system following topical use.


Q: Why do official documents mention a certain risk factor for 8X?

Official documents mention risk factors, such as the potential for local irritation or hair discoloration, because these effects were documented in clinical trials or observed during post-marketing surveillance. The documentation serves to inform of known outcomes based on research and surveillance.


Q: What are the less common, but serious, side effects associated with 8X?

Serious adverse events are rare and typically involve signs of an allergic reaction (such as swelling or trouble breathing) or local reactions that suggest sensitivity or chemical irritation. Official guidelines indicate that product discontinuation is required if signs of sensitivity or irritation occur.


Q: Is there a specific time of day that 8X is typically taken?

The official instructions specify the frequency (twice per week) and a minimum interval (3 days between applications). However, the regulatory documents do not specify a particular time of day for use.


Q: Is it possible to become dependent on 8X?

Official regulatory information does not suggest that this topical product is habit-forming or carries a risk of physical or psychological dependence.


Q: Does 8X require a special prescription or form?

The product contains active ingredients that are used in both prescription (Rx) and Over-the-Counter (OTC) formulations, depending on their concentration. This means the need for a prescription for 8X specifically can vary.


Q: How is the safety of 8X monitored after it has been approved?

The safety of the medicine is continually monitored via Post-Marketing Observations. This is a system where users and healthcare providers voluntarily report any reactions or unexpected effects that occur after the product has been made available to the public.

How should 8X be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of this medicated shampoo must strictly comply with official regulatory labeling to ensure product stability and safety.

Storage Category Requirement from Official Labeling
Temperature Store at controlled room temperature (15 C to 30 C or 59 F to 86 F).
Handling Keep from freezing and excessive heat. Avoid storage near open flame due to the flammability caution for this class of product.
Container Rule Keep the container tightly closed in the original packaging when not in use.
Stability The product should be used within 8 weeks after first opening the container.
Child Safety Keep out of the reach of children, as required by government safety labeling.
Disposal Safely throw away any unused or expired product once treatment is complete. Do not flush the medicine down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of 8X found in:

A-Z Index: